Subsequently, based on immunohistochemistry results patients were classified into five distinct molecular subtypes: luminal A, luminal B (HER2−), luminal B (HER2+), HER2+, and triple-negative breast cancer (TNBC). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.